Psoriasis, biological drugs and Coronavirus Disease 2019: Real life experience of two Italian provinces

Martina Vispi,1 Teresa Corradini,2 Camilla Peccianti,1 Luca Feci,1 Laura Casini,1 Chiara Pisani,1 Susanna Fabbroni,1 Paola Corsetti,2 Margherita Croatto,2 Michele Pellegrino1
1Dermatology Unit, Misericordia Hospital, Grosseto; 2Dermatology Unit, Pordenone Hospital, Pordenone, Italy

Abstract

On January 30, 2020, World Health Organization (WHO) stated that a new coronavirus disease outbreak [CoronaVirus Disease - 19 (COVID-19)] was an international public health emergency. Many news, often fake ones, about the derived pandemic rapidly spread along the media, thus leading many dermatological patients to identify as “risk category” and sometimes discontinue treatments by themselves. The Dermatology Units in Grosseto and Pordenone simultaneously carried out a data collection by remote-conducted visits, evaluating the incidence of COVID-19 in psoriatic patients. Only 1 patient (close contact of a case) as part of the psoriasis analyzed group was tested and turned out to be positive for SARS-CoV-2, developing no symptoms during the observation period. The collected information may suggest that psoriasis, biotechnologically treated or not, cannot promote or aggravate the clinical trend of the SARS-CoV-2 infection, hence stopping systemic therapy in negative or clinically free SARS-CoV-2 patients is not recommended in general.

Introduction

On December 31, 2019, Chinese health authorities reported that an epidemic outbreak of atypical pneumonia of unknown etiology had developed in the city of Wuhan (central-eastern China). A few days later, the Chinese Center for Disease Control announced that the causative agent, a new coronavirus provisionally called 2019 - new CoronaVirus (2019-nCoV), had been identified.1

On 30 January 2020, World Health Organization (WHO) stated that the new coronavirus outbreak, then called Severe Acute Respiratory Syndrome - Coronavirus - 2 (SARS-CoV-2), responsible of the so called CoRoNaVirus Disease - 19 (COVID-19), was an international public health emergency.2 After its sequencing, the International Committee on Taxonomy of Viruses (ICTV) developed its taxonomy,3 confirming that it is a virus of the Coronaviridae family, which shares 79.5% of the gene sequence with the Severe Acute Respiratory Syndrome (SARS) coronavirus4 and 96.2% with that of a bat coronavirus (Rhinolophus affinis species) which is supposed to be the animal reservoir species with direct transmission to humans or through other intermediate hosts, not better identified yet.5 WHO reiterated that possible interhuman transmission modalities were by air, with salvia and aerosol from secretions of the upper airways, through conjunctival and oral mucous membranes, by direct contact and/or by oral-fecal route. Although the main transmission mechanism is linked to contact with people who have contracted the infection and are symptomatic for the disease, the possibility of transmission from infected but asymptomatic people has not been denied,6 similarly to what is already known for other coronaviruses like the Middle East Respiratory Syndrome - Coronavirus (MERS-CoV).

The SARS-CoV-2 pandemic, as a “health tsunami”, quickly conquered the front pages of newspapers, news programs, websites. Data and information quickly and frantically followed each other and often became a source of fake news and baseless scientific information. In particular, social media have given communication opportunities to anyone with access to the network with the inevitable consequence that the message transmitted often turns out to be distorted, de-contextualized or even untrue. The consequence of this redundancy of information often of inadequate and confusing quality has led many patients with chronic dermatological pathologies such as psoriasis, Hidradenitis Suppurativa (HS), or atopy to identify themselves as “risk category” not only for the underlying pathology, but also and above all for the biotechnological drugs they were in therapy with, suspending them on their own initiative. This self-management probably took place to protect themselves from what many patients call the “magnet effect”, almost as if the dermatosis and/or the “immunosuppressant” drug were capable of magnetic attraction towards SARS-CoV-2 and so COVID-19.

Trying to stem this invasive phenomenon and to evaluate at the same time the incidence of COVID-19 in dermatological patients, focusing on psoriatic ones, the Dermatology Units in Grosseto and Pordenone simultaneously carried out a data collection, by remote-conducted visits, concerning hundreds of psoriasis patients being treated with biological drugs.

Materials and Methods

For this purpose, 246 patients (104 females and 142 males), in an age range of 21-90 and with a mean age of 56 years old (Figure 1), with moderate-severe psoriasis receiving biologic or small molecular drug therapy on March 1, 2020, underwent a virtual check-up and a series of pandemic-related questions during the two last weeks of April. All patients were contacted and interviewed through the aid of different video/audio devices (smartphone, computer, tablet or phone), according to what the individual patient possessed; they were divided into different groups based on the biotechnological or small molecular drug in use (Table 1).

Regardless of the ongoing therapy, only 1 patient, in therapy with ustekinumab (Stelara, Janssen Biotech Inc, Horsham, PA) tested positive for SARS-CoV-2, although asymptomatic. The swab, which had allowed the identification of the subject and the consequent home isolation, had been carried out because of the positivity of a cohabitant who had complained of persistent fever and difficulty in breathing. This patient, who had been carrying out therapy with the biotech drug on a quarterly basis, as per therapeutic protocol, was formally declared SARS-CoV-2 free after perfor-
SARS-CoV-2 positive cases are shown in red.

Figure 1. Case distribution by age (age range 21-90 years old; mean age 56 years old).

Table 1. The patients were divided into different groups based on the biotechnological or small molecular drug in use.

<table>
<thead>
<tr>
<th>Ongoing therapy</th>
<th>Number of patients</th>
<th>Percentage of patients</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ustekinumab</td>
<td>61</td>
<td>25%</td>
</tr>
<tr>
<td>Etanercept</td>
<td>55</td>
<td>22%</td>
</tr>
<tr>
<td>Secukinumab</td>
<td>37</td>
<td>15%</td>
</tr>
<tr>
<td>Adalimumab</td>
<td>36</td>
<td>15%</td>
</tr>
<tr>
<td>Apremilast</td>
<td>22</td>
<td>9%</td>
</tr>
<tr>
<td>Ixekizumab</td>
<td>14</td>
<td>6%</td>
</tr>
<tr>
<td>Guselkumab</td>
<td>10</td>
<td>4%</td>
</tr>
<tr>
<td>Risankizumab</td>
<td>6</td>
<td>3%</td>
</tr>
<tr>
<td>Infliximab</td>
<td>3</td>
<td>1%</td>
</tr>
<tr>
<td>Brodalumab</td>
<td>1</td>
<td>0%</td>
</tr>
<tr>
<td>Certolizumab</td>
<td>1</td>
<td>0%</td>
</tr>
</tbody>
</table>

Only 1 patient (close contact of a case) as part of the psoriasis analyzed group was tested and turned out to be positive for SARS-CoV-2, developing no symptoms during the observation period. The collected information may suggest that psoriasis, biologically treated or not, cannot promote or aggravate the clinical trend of the SARS-CoV-2 infection, hence stopping systemic therapy in negative or clinically free patients is not recommended in general.

Discussion

Despite what has been circulating by some news outlets, our data are in line with what has been recorded by the Higher Institute of Health and document that psoriasis, regardless of the use of biologic drugs, is not a chronic comorbidity which can promote or aggravate the clinical trend of the SARS-CoV-2 infection. With regard to biotechnology therapies, it is likely that these drugs, by significantly reducing the inflammatory cascade typical of psoriasis, may even help to reduce the cytochimic storm recorded in many positive COVID-19 patients.

Lebwohl et al. have recently published in the literature overall infection rates as well as rates of upper respiratory tract infections and nasopharyngitis for each available biologic agent versus its placebo control by extrapolating published data from pivotal trials. They suggest that, even if it is not known whether biologic therapies make patients being more susceptible to coronavirus, in the pre-coronavirus era, respiratory infection percentages were similar to those with placebo. Discontinuation of some biologies could have worse effects, such as loss of response when treatments are reintroduced or even result in the formation of antibodies to the discontinued biologic. As therapy prosecution during COVID-19 emergency seems to strictly depend on the quality of information that patients acquire, dermatologists should inform them correctly and exhaustively to increase patients’ adherence to treatments.

In another paper written by Brownstone et al., similar considerations are made; however, it is pointed out that, as SARS-CoV-2 is a novel pathogen associated with mortality in a subset of patients, a cautious approach is warranted and so that treatment decisions should be made taking into consideration each patient’s individualized condition. Actually, treatment decisions should always be made on the basis of dialogue between patient and physician; fortunately,
all this could take place during the lockdown period too, by remote surveillance of patients. An Italian experience in teledermatologic monitoring showed that it was effective in preventing unnecessary worsening of severe chronic skin diseases and poor outcomes due to withdrawal of current therapy.11

One thing to take into consideration too, is the lack of adherence to vaccination programmes (around 15%), probably to be linked to the media wave of “no-Vax”, which could open up negative scenarios once a useful vaccine against SARS-CoV-2 is obtained.

Both our real life data and current evidence recommend not to stop systemic psoriasis therapy in negative or clinically free SARS-CoV-2 patients. Our experience aims to be a small contribution to spreading the message of not interrupting current therapy and keeping in touch with one’s own dermatologist for any clarification and doubt.

References